Ozempic®

About Ozempic®

Ozempic® (semaglutide) is FDA-approved for the treatment of type 2 diabetes. Often prescribed off-label for weight loss. Same active ingredient as Wegovy®.

Manufacturer / source: Novo Nordisk

How it compares

For tirzepatide forms head-to-head, see comparison page. For trial data, see clinical research.

Brand context & FDA status

Ozempic is Novo Nordisk's brand name for semaglutide for type 2 diabetes. FDA-approved on December 5, 2017 for glycemic control in adults with type 2 diabetes mellitus. In 2020, the FDA expanded the label to include cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease. Ozempic shares the same active ingredient as Wegovy and Rybelsus.

Mechanism of action

GLP-1 receptor agonist. Glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and central appetite suppression. Long half-life (~7 days) enables once-weekly subcutaneous administration.

Clinical efficacy data

The SUSTAIN clinical program in type 2 diabetes. SUSTAIN-1 through SUSTAIN-7 demonstrated A1C reductions ranging approximately 1.3–1.8% across doses and comparator arms. SUSTAIN-6 (NEJM 2016) established a 26% reduction in major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk, supporting the 2020 CV risk reduction label.

FDA-approved indications

FDA-approved indications: (1) glycemic control in adults with type 2 diabetes; (2) cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease. Not FDA-approved for weight loss.

Dosing & titration

Titration: 0.25 mg weekly for four weeks (initiation dose, not for glycemic effect), then 0.5 mg weekly. After at least four weeks at 0.5 mg, dose may be increased to 1.0 mg weekly, and after a further four weeks to a maximum of 2.0 mg weekly if additional glycemic control is needed.

Safety profile & adverse events

Most common adverse events: nausea, vomiting, diarrhea, abdominal pain, constipation. Same boxed warning for thyroid C-cell tumor risk. Contraindicated with personal or family history of MTC or MEN 2. Monitor for pancreatitis, retinopathy complications, hypoglycemia (especially with insulin or sulfonylureas), gallbladder events, acute kidney injury.

Cost & access in 2026

Ozempic list price in 2026 is approximately $970 per month. Widely covered by commercial insurance and most state Medicaid programs for type 2 diabetes with prior authorization. Medicare Part D covers Ozempic for diabetes. Off-label prescribing for weight loss generally is not covered, contributing to shortages and insurance friction in 2023–2024.

Frequently asked questions

Is Ozempic for weight loss?

Ozempic is FDA-approved only for type 2 diabetes and cardiovascular risk reduction in patients with diabetes. While weight loss is a common effect of semaglutide and Ozempic is widely prescribed off-label for weight management, the FDA-approved weight-loss product containing semaglutide is Wegovy.

How is Ozempic injected?

Ozempic is a once-weekly subcutaneous injection administered with a pre-filled, multi-dose pen. Injection sites include the abdomen, thigh, or upper arm. The same day of the week each week is preferred for consistency.

Will Ozempic help me lose weight if I don't have diabetes?

Semaglutide produces weight loss in non-diabetic patients in clinical trials. However, prescribing Ozempic specifically for weight loss in non-diabetic patients is off-label, and most insurance plans will not cover it for this purpose. Wegovy is the FDA-approved semaglutide product for weight management.